Company
ASX:PIQ
Proteomics International Laboratories Ltd is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The company specialises in proteomics – the industrial scale study of the structure and function of proteins.
37 stories · page 2 of 2
Proteomics International Laboratories Ltd (ASX:PIQ) has reached a strategic milestone in its commercialisation pathway for PromarkerD, a predictive test kit for diabetic kidney disease.
Growth is being driven by the generic protein drug market as the sector seeks to replicate the multiple billion dollar drugs that are coming off patent.
PILL has already operated successfully in India since 2004, and therefore can build on this established exposure. The company will target this rapidly growing global biotech hub forecast to be worth $US100 billion by 2025.
Therapeutic Drug Discovery is one of PILL’s core business areas and is a major growth market. The company is specifically targeting the discovery of new analgesic (painkilling) and antibiotics compounds and will test 50 - 100 venoms i
Proteomics International Laboratories has received an R&D tax incentive as a global push to commercialise company products gains traction.
The Australian All Ordinaries closed flat today at 5,295 points despite the Australian Bureau of Statistics posting international trade balance figures that revealed higher exports and the narrowest trade deficit since March for the local e
Proteomics International Laboratories leadership is following up recent recognition of its global marketing achievements with a string of international engagements and a special emphasis on Asian markets.
The patent is a critical milestone in the development of the Diagnostic Test for Diabetic Kidney Disease in the world’s largest health care market. Investors have responded to the patent.
The Australian All Ordinaries closed flat at 5,305 points today, with most sectors finishing slightly in the red.
Proteomics International Laboratories reinforced its investment case Friday by taking home an industry award for outstanding international success in the medical, healthcare, and biotechnology fields.
Proteomics is pressing forward with multiple major upside opportunities as a key health test internationalises and an options issue unfolds. The company’s proteomics-based technology platform is developing next-generation diagnostic t
The ground breaking predictive test for diabetic kidney disease is a world first and could see "big pharma" taking a firm interest in Proteomics', with no available test for predicting the onset of kidney disease.
